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Abstract
Objective
To determine the value of quantitative MRI in providing imaging biomarkers for disease in 20
different upper and lower leg muscles of patients with myotonic dystrophy type 1 (DM1).
Methods
We acquired images covering these muscles in 33 genetically and clinically well-characterized
patients with DM1 and 10 unaffected controls. MRIs were recorded with a Dixon method to
determine muscle fat fraction, muscle volume, and contractile muscle volume, and a multi-echo
spin-echo sequence was used to determine T2 water relaxation time (T2water), reflecting
putative edema.
Results
Muscles in patients with DM1 had higher fat fractions thanmuscles of controls (15.6 ± 11.1% vs
3.7 ± 1.5%). In addition, patients had smaller muscle volumes (902 ± 232 vs 1,097 ± 251 cm3),
smaller contractile muscle volumes (779 ± 247 vs 1,054 ± 246 cm3), and increased T2water
(33.4 ± 1.0 vs 31.9 ± 0.6 milliseconds), indicating atrophy and edema, respectively. Lower leg
muscles were affected most frequently, especially the gastrocnemius medialis and soleus.
Distribution of fat content per muscle indicated gradual fat infiltration in DM1. Between-
patient variation in fat fraction was explained by age (≈45%), and another ≈14% was explained
by estimated progenitor CTG repeat length (r2 = 0.485) and somatic instability (r2 = 0.590).
Fat fraction correlated with the 6-minute walk test (r = −0.553) andmuscular impairment rating
scale (r = 0.537) and revealed subclinical muscle involvement.
Conclusion
This cross-sectional quantitative MRI study of 20 different lower extremity muscles in patients
with DM1 revealed abnormal values for muscle fat fraction, volume, and T2water, which
therefore may serve as objective biomarkers to assess disease state of skeletal muscles in these
patients.
ClinicalTrials.gov identifier
NCT02118779.
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Myotonic dystrophy type 1 (DM1) is a multisystem disease
characterized by progressive muscle weakness, myotonia, and
cognitive dysfunction.1,2 Its genetic cause is an expansion of
a CTG trinucleotide repeat in the dystrophia myotonica
protein kinase (DMPK) gene, whereby CTG repeat length
correlates with disease severity.3,4
Although currently DM1 cannot be treated, promising ther-
apeutic approaches are emerging.3,5 Objective assessment of
these approaches in clinical trials requires quantitative bio-
markers that can assess disease in individual muscles. More-
over, such biomarkers are important to follow the natural
progression of DM1 and to understand its pathophysiologic
mechanisms. Because MRI is a noninvasive, quantitative
method that can provide relevant biomarkers such as muscle
volume, fat fraction, and T2 relaxation time of water, it is well
suited to study neuromuscular disorders.6–8 These bio-
markers report the respective pathologic processes of muscle
atrophy, fatty infiltration, and intracellular or extracellular
edema, the last assumed to associate with disease activity.6
Previously, it has been shown that each muscle appears to be
affected differently in DM1.9
The aim of our study is therefore to determine the value of
quantitative muscle MRI to provide imaging biomarkers for
fat infiltration, muscle mass, and T2 relaxation of putative
edema in a broad set of upper and lower leg muscles in well-
characterized patients with DM1. We first determined
whether these imaging measures differ between patients and
unaffected controls. Second, we examined whether DM1
exhibits a specific pattern and distribution of muscular fat
infiltration. Third, we associated these MRI measures with
age, CTG repeat length, and clinical outcomes.
Methods
Participants
In this cross-sectional study, we included participants with
genetically confirmed DM1 and unaffected, apparently
healthy controls comparable in age and sex. The patients with
DM1 participated in the multicenter randomized controlled
Observational Prolonged Trial in Myotonic Dystrophy Type
1 (OPTIMISTIC) trial.10 We invited patients from the study
sites in the Netherlands (Radboud University Medical
Center, Nijmegen) and France (Henri Mondor University
Hospital, Paris). Participants who had a pacemaker, a pros-
thetic implant in the lower extremity, or claustrophobia or
were unable to lie in the supine position for 60 minutes were
excluded.
Standard protocol approvals, registrations,
and patient consents
This study was conducted according to the principles of the
Declaration of Helsinki (October 2013 version) and the
Medical Research Involving Human Subjects Act. The local
medical ethics committees approved this study, and prior written
informed consent was obtained from all participants. This trial is
registered with ClinicalTrials.gov (NCT02118779).
Clinical and genetic assessment of patients
with DM1
The complete study design for the clinical and genetic as-
sessment has been described.10 Physical capacity was evalu-
ated by performing a 6-minute walk test (6MWT), and
disease severity was assessed with the muscular impairment
rating scale (MIRS).11 Moreover, activity and social partici-
pation were assessed with the DM1-Activ-c questionnaire,12
and fatigue was evaluated with the fatigue severity subscale of
the Checklist Individual Strength.13 At the time of re-
cruitment for OPTIMISTIC, blood DNA samples were taken
and subjected to small-pool PCR and Southern blotting. Be-
cause only a small amount (300 pg) of DNA template was
used, distinct bands of varying lengths derived from the CTG
repeat expansion were observed. Somatic instability usually
results in the repeats increasing in length over time, wherefore
the lower edge of these bands on the blot was used to estimate
the inherited, or progenitor, allele length (CTGePAL) and the
densest region of bands was used to estimate the most fre-
quent, or modal, repeat length at time of sampling
(CTGmodal). Somatic instability was estimated by subtracting
CTGmodal from CTGePAL. Furthermore, we tested for the
presence of AciI-sensitive variant repeats in the expanded al-
lele because they may result in milder symptoms and delayed
disease onset.14–16 Individual-specific residual variation in
somatic instability (CTGResSI) not accounted for by age at
sampling, estimated progenitor allele length, or presence of
variant repeats was calculated with data from the entire OP-
TIMISTIC cohort.
MRI acquisition
The upper and lower legs of patients and unaffected controls
were examined with MRI, with random selection of the right
or left leg. In patients, this MRI took place within 1 month of
recruitment for the OPTIMISTIC trial. The MRI was per-
formed on 3T MRI systems (Siemens, Tim TRIO, [Nijme-
gen] or Magnetom Verio [Paris], Erlangen, Germany) using
a spine coil combined with phased arrays placed around the
lower extremity. All images were in the transverse plane, po-
sitioned at the thickest part of the lower leg and middle of the
femur in the upper leg, and oriented orthogonal to the tibia or
Glossary
DM1 = myotonic dystrophy type 1; DMPK = dystrophia myotonica protein kinase; FOV = field of view; MIRS = muscular
impairment rating scale; OPTIMISTIC = Observational Prolonged Trial in Myotonic Dystrophy Type 1; 6MWT = 6-minute
walk test; TIRM = turbo inversion recovery magnitude; TE = echo time; TR = repetition time.
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femur bone, respectively (figure 1). First, we collected T1-
weighted spin echo images (repetition time [TR] 670 milli-
seconds, echo time 10milliseconds, field of view [FOV] 192 ×
192 mm, voxel size 1 × 1 × 5 mm, number of slices 27, slice
gap 0 mm). Thereafter, we acquired turbo inversion recovery
magnitude (TIRM) images with a similar FOV, resolution,
and slices (TR 4,000 milliseconds, echo time 41 milliseconds,
inversion time 220 milliseconds). Furthermore, we collected
data using 3D Dixon sequences (TR 10 milliseconds, flip
angle 3°, FOV 256 × 192 mm, voxel size 1 × 1 × 5 mm,
number slices 32) in either a 2-point version (TE1/TE2 =
2.45/3.675milliseconds) or 3-point version (TE1/TE2/TE3 =
2.31/3.68/5.07 milliseconds). Finally, at the Nijmegen site,
multi-echo spin-echo images were acquired (TR 3,720 milli-
seconds, echo train length 17, echo-spacing 8 milliseconds,
voxel size 1.5 × 1.5 × 10 mm, number of slices 5, slice gap
20 mm).
Data analysis
Semiquantitative MRI
An experienced radiologist (M.J.P.) scored 7 lower leg and 12
upper leg muscles (figure 1, B and C) semiquantitatively for
signs of fat infiltration and putative edema on T1-weighted
spin echo and TIRM images, respectively. For the T1-
weighted images, the ordinal Lamminen score (range 1–4)
was used, in which 1 represents normal muscle signal intensity
and 4 reflects a total, homogeneous hyperintense signal
change in the entire muscle.17 The TIRM images were scored
with the ordinal Malattia score (range 0–2), with 0 meaning
no muscle signal abnormalities and 2 indicating a high degree
of signal hyperintensity.18 The Lamminen and Malattia in-
dividual muscle scores of each participant were summed over
all lower extremity muscles for comparison between patients
with DM1 and unaffected controls.
Quantitative MRI
Data analysis was performed with Matlab version 2014b
(MathWorks, Natick, MA). A fat fraction map, with voxel values
ranging from 0% to 100%, was calculated from the Dixon se-
quence data by voxel-wise dividing the signal intensity of the fat
image by the summed signal intensity of the fat and water image:
Fat Fraction map =
Fat
Fat +Water
× 100% (1)
The T2 relaxation time of muscle water (T2water in milli-
seconds) was determined per voxel by fitting multi–spin echo
data with a bicomponent extended-phase graph model (ap-
pendix available from Dryad, doi.org/10.5061/dryad.
4nb96c1).19,20 Increased T2water is thought to reflect putative
edema and disease activity.
For the quantitative evaluation, we analyzed the same 19
lower extremity muscles as evaluated semiquantitatively, plus
the flexor digitorum longus, i.e., in total 8 calf and 12 thigh
muscles. They were delineated on 5 distal, middle, and
proximal slices of the Dixon images of the upper and lower leg
using Medical Image Processing, Analysis, and Visualization
(mipav.cit.nih.gov), thereby avoiding subcutaneous fat con-
tamination (figure 1, A-C). Furthermore, delineation was
performed on the 5 slices of the Dixon images corresponding
in position to the T2water map and transposed to this T2water
Figure 1 Positioning of image slices, muscle delineation,
and data processing pipeline
(A) Positioning of image slices at the lower and upper leg. Large blocks
indicate the total area covered byMRI. Muscles were delineated on 17 slices
of the Dixon images, depicted in light and dark gray using the out-phase
images, water images, and fat fraction map. Dark gray slices correspond in
slice position to the T2 water relaxation time (T2water) map. (B) Example of
muscle delineation of the 12 quantitatively analyzed upper leg muscles on
the fat fraction map. (C) Example of muscle delineation of the 8 quantita-
tively analyzed lower leg muscles on the fat fraction map. (D) Schematic
overview of the data processing pipeline. AM/AL = adductormagnus/longus;
BFS/BFL = biceps femoris short/long head; EDL = extensor digitorum longus;
FDL = flexor digitorum longus; G = gracilis; GL/GM = gastrocnemius lateralis/
medialis; P = peroneus; RF = rectus femoris; S = sartorius; SM = semi-
membranosus; SOL = soleus; ST = semitendinosus; TA/TP = tibialis anterior/
posterior; VL/VI/VM = vastus lateralis/intermedius/medialis.
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map (figure 1A). Average fat fraction, T2water, and estimated
muscle volume were determined for each muscle (figure 1D).
Average fat fraction was defined as the mean over all voxels,
and muscle volume was defined as the number of voxels
multiplied by the voxel volume using the 15 delineated slices
of the fat fractionmap. In addition, contractile muscle volume,
i.e., the remaining muscle tissue still able to contract, was
calculated as follows:
contractile muscle volume = muscle volume × ð1 − fat fractionÞ (2)
To obtain T2water, the voxels with severe fat infiltration were
excluded (data available from Dryad, doi.org/10.5061/
dryad.4nb96c1) because sufficient water signal is required
for reliable fitting of T2water.
21 If the remaining number of
voxels was >10% of the total number of voxels in that
muscle, T2water was calculated as the average over these
voxels in the 5 T2water map slices. Muscles were excluded
from the analysis if visual inspection revealed the presence
of movement artifacts. For the fat fraction and contractile
muscle volume analysis, muscles were also excluded if arti-
facts in the fat/water reconstruction made the fat fraction
estimate unreliable.
Outcomes for the 20 individual muscles were combined,
resulting in per participant a value for the entire lower extremity
and a value for the lower and upper leg level (figure 1D). For the
fat fraction and T2water, muscles were combined by taking the
average over all 20 muscles per participant and the average over
the 8 lower leg and 12 upper leg muscles separately. For the
muscle volume and contractile muscle volume, we took the sum
of these muscles per participant. The outcome measures for the
entire lower extremitywere calculated only if upper and lower leg
muscle data were available.
To investigate whether muscles with signs of fat infiltration
differ in T2water with muscles without fat infiltration, muscles
were divided into 2 groups based on their fat fraction. For all
20 muscles, a cutoff value was defined as the average fat
fraction + 2 SDs of that muscle in unaffected controls (figure
1D). It was observed that, in unaffected controls, T2water
differed between muscles; e.g., the average T2water was 27.6
milliseconds in the rectus femoris and 33.8 milliseconds in the
gastrocnemius medialis (Friedman test, p < 0.001, figure e-4
available from Dryad, doi.org/10.5061/dryad.4nb96c1).
Therefore, for each muscle, we determined the absolute dif-
ference in milliseconds relative to the average T2water over the
10 unaffected controls in that particular muscle (rT2water).
Thereafter, we averaged per participant the rT2water of the
individual non–fat-infiltrated muscles and rT2water of the fat
infiltrated muscles to obtain for both a value for the lower
extremity (figure 1D).
Statistical analysis
Statistical analysis was performed with IBM SPSS Statistics
version 22 (SPSS, Chicago, IL) or R statistics using the
RStudio package (R Foundation for Statistical Computing,
Vienna, Austria).22,23 Differences between unaffected
controls and patients with DM1 were assessed with a 2-tailed
Mann-Whitney U test. A 2-tailed 1-sample t test to zero was
applied to determine whether rT2water in DM1 differed from
that in unaffected controls. The difference in rT2water be-
tween non–fat-infiltrated and fat-infiltrated muscles was
evaluated with a 2-tailed Wilcoxon signed-rank test. Fat
fraction and T2water were correlated with the Lamminen and
Malattia scoring using the Spearman correlation, re-
spectively. Multivariate linear regression was applied to
predict fat fraction using age, CTGePAL, and CTGResSI. Fat
fraction, age, and CTGePAL were log transformed to increase
linearity and to improve normality. Model selection was
based on the Akaike information criterion for each model
using a backward stepwise selection procedure implemented
with the step function in R.24 Whole lower extremity
quantitative MRI measures were correlated with the MIRS
and 6MWT. In addition, the 6MWT was correlated with
quantitative MRI outcome measures of relevant muscle
groups (knee extensors, knee flexors, ankle dorsiflexors, and
ankle plantarflexors) using Bonferroni correction. Signifi-
cance was set at p = 0.05. Data are presented as mean ± SD
unless otherwise stated.
Data availability
We encourage researchers wishing to access the generated
anonymized data to submit a request to the corresponding
author. Requests for access will be reviewed by a panel, and
a data access agreement needs to be signed.
Results
Participants
The age and fraction of men to women were not different
between the 33 patients with DM1 (24 in Nijmegen, 9 in
Paris) and 10 unaffected controls (table 1). The clinical forms
by which the patients with DM1 were affected are presented
in table 1. According to the clinical scores such as the MIRS,
DM1-Activ-c, 6MWT, and Checklist Individual Strength-
fatigue, patients varied from mildly to severely affected and
exhibited a wide range of CTG repeat lengths (table 1).
Semiquantitative evaluation of the MRI data included 615
muscles in patients with DM1 and 190 muscles in unaffected
controls; quantitative evaluation included 633 muscles in
patients with DM1 and 200 muscles in unaffected controls.
Twelve upper leg muscles were not analyzed because 1 patient
could not lie in the supine position long enough to acquire
data with all MRI sequences. Further details on the number of
muscles and participants analyzed per MRI outcome measure
are presented in table 2.
MRI outcome measures differ between
patients with DM1 and unaffected controls
The T1-weightedMRIs of lower extremity muscles in patients
with DM1 displayed hyperintense lesions indicative of fat
infiltration (figure 2, A–D). The semiquantitative Lamminen
score of these lesions was higher for muscles of patients with
DM1 compared to unaffected controls (sum Lamminenmean
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± SD score: DM1, 28.3 ± 9.4; controls, 19.2 ± 0.4; p = 0.001;
table 2), with a more substantial relative increase in the lower
leg muscles than in the upper leg muscles.
In TIRM images of patients with DM1, we observed hyper-
intense areas indicative for edema (figure 2, E–H). The
semiquantitative Malattia score of these hyperintense lesions
was higher compared to that of controls (sum Malattia score:
DM1, 9.7 ± 7.6; controls, 0.4 ± 0.7, p < 0.001; table 2). Most
TIRM-positive lesions were observed in the lower leg. In the
33 scored patients, the number of lower leg muscles with
these lesions ranged from 20 tibialis posterior muscles
(Malattia score >0) to 25 tibialis anterior and gastrocnemius
medialis muscles. In the upper leg, the vastus lateralis and
intermedius were most often TIRM positive (12 and 14
muscles, respectively), and only 4 of the scored gracilis, sar-
torius, and adductor longus muscles were TIRM positive. Of
the 422 muscles that showed no fat infiltration (Lamminen
score 1), 83 muscles (20%) showed hyperintense areas on the
TIRM images (i.e., Malattia score 1 or 2). Detailed results on
the individual Lamminen and Malattia scores are presented in
table e-1 and figure e-1 (available from Dryad, doi.org/10.
5061/dryad.4nb96c1).
For the quantitative determination of muscle fat fraction,
muscle volume, and contractile muscle volume, we analyzed
the MRIs obtained with the Dixon method (figure 3 and table
2). These analyses revealed an increased fat fraction for
patients with DM1 compared to unaffected controls: 15.6 ±
11.1% vs 3.7 ± 1.5%, respectively (p < 0.001; figure 3A).
Analysis of these images also revealed that muscle volume was
reduced in patients with DM1 (DM1: 902 ± 232 cm3; con-
trols: 1,097 ± 251 cm3; p = 0.028), as well as contractile
muscle volume (DM1: 779 ± 247 cm3; controls: 1,054 ± 246
cm3; p = 0.008) (figure 3, B and C).
To determine T2water values as a quantitative parameter for
putative edema-associated disease activity, we analyzed MRIs
of the lower extremity obtained with a multi-echo spin-echo
sequence. The T2water maps derived from these images typi-
cally reveal increased T2water in some muscles of patients with
DM1, e.g., in the adductor magnus (figure 3D). On average,
T2water was elevated in muscles of patients with DM1 com-
pared to unaffected controls: 33.5 ± 1.0 vs 31.9 ± 0.6 milli-
seconds respectively (p < 0.001; figure 3E and table 2). To
account for differences in intrinsic T2water between muscles,
we also evaluated rT2water to quantify edema-associated dis-
ease activity relative to the muscles of unaffected controls.
rT2water was elevated in non–fat-infiltrated muscles (+1.4 ±
1.5 milliseconds, p < 0.001) and fat-infiltrated muscles (+2.4 ±
1.3 milliseconds, p < 0.001) and elevated in fat-infiltrated vs
non–fat-infiltrated muscles (p = 0.015; figure 3F). Although
these rT2water findings are highly significant at the group level,
some muscles of patients with DM1 also showed normal
T2water.
The quantitative values for fat fraction and T2water in DM1
muscles correlate well with the corresponding semi-
quantitative scores (Lamminen score vs fat fraction: ρ = 0.631,
p < 0.001; Malattia score vs T2water: ρ = 0.400, p < 0.001).
Average values for quantitative MRI measures per individual
muscle are presented in figures e-2 through e-5 (available
from Dryad, doi.org/10.5061/dryad.4nb96c1).
To assess the prevalence of fat infiltration in individual mus-
cles of patients with DM1, we analyzed the fat fractions per
Table 1 Participant characteristics, patient clinical
performance, and CTG repeat length
Patients with
DM1 (n = 33)
Unaffected
controls (n = 10)
Patient characteristics
Age, y 45 ± 12 45 ± 14
M/F, n (% male) 18/15 (55) 5/10 (50)
MIRS score, median
(minimum–maximum)
3 (1–5)
Clinical classification, n
Congenital form (age at
onset, first month)
0
Infantile form (age at
onset, 1 mo–10 y)
3
Juvenile form (age at
onset, 10–20 y)
12
Adult form (age at onset,
20–40 y)
15
Late-onset form (age at
onset, >40 y)
3
Genetics: CTG repeat length
CTGePAL 241 ± 117
CTGmodal 446 ± 230
Somatic instability 205 ± 142
AciI-sensitive variant
repeat, n patients
4
CTGResSI −0.2 ± 1.2
Physical activity and
capacity
DM1-Activ-c score 59 ± 18
6MWT, m 417 ± 111
Fatigue
CIS-fatigue 44 ± 7
Abbreviations: CIS-fatigue = Checklist Individual Strength, fatigue subscale;
CTGePAL = estimated inherited progenitor CTG repeat length; CTGmodal =
modal CTG repeat length in blood at time of recruitment; CTGResSI = in-
dividual-specific residual variation in somatic instability; MIRS = muscular
impairment rating scale; 6MWT = 6-minute walk test.
Somatic instability is the increase in CTG repeat length over the lifetime,
defined as CTGmodal— CTGePAL. All data are presented as mean ± SD unless
stated otherwise.
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muscle (figure 4, A–D). Fat fraction was higher in lower leg
muscles compared to upper leg muscles (lower leg 22.5 ±
18.2%, upper leg 10.3 ± 7.6%; Wilcoxon signed rank
test, p = 0.001). Among the lower leg muscles, the gas-
trocnemius medialis and soleus exhibited the highest fat
fractions, while the vastus intermedius had the highest fat
fraction in the upper leg (figure 4, E and F). The tibialis
posterior appeared to be spared in the lower leg. The
varying fat fractions in individual lower extremity muscles
exhibited a pyramid-like distribution, with fewer highly fat-
infiltrated muscles than non–fat-infiltrated muscles, in-
dicating a gradual process of fat infiltration (figure 4, G
and H).
Effect of age and CTG repeat length on muscle
fat infiltration
To assess the effect of age and CTG repeat length on fat
infiltration, we applied a multivariate linear regression model,
which uncovered age as the primary predictor of a partic-
ipant’s average lower extremity fat fraction (r2 = 0.447, p <
0.001). Fitting of the data was further improved by in-
corporating CTGePAL (r
2 = 0.485, model p value, p < 0.001,
parameter p value; age: p < 0.001; CTGePAL: p = 0.090) and
CTGResSI with interactions between all parameters (r
2 =
0.590, p = 0.001; see also table e-2 available from Dryad, doi.
org/10.5061/dryad.4nb96c1). For the latter model, none of
the individual parameters reached statistical significance, but
Table 2 Semiquantitative and quantitative values of MRI measures in patients with DM1 vs unaffected controls
Participants, n Muscles, n Outcome values
Patients with
DM1
Healthy
controls
Patients with
DM1
Healthy
controls
Patients with
DM1
Healthy
controls
p
Value
Lamminen sum score
Lower extremity 32 10 608 190 28.3 ± 9.4 19.2 ± 0.4 0.001
Lower leg 33 10 231 70 13.4 ± 5.8 7.2 ± 0.4 0.001
Upper leg 32 10 384 120 15.0 ± 4.3 12.0 ± 0 0.007
Malattia sum score
Lower extremity 32 10 608 190 9.7 ± 7.6 0.4 ± 0.7 <0.001
Lower leg 33 10 231 70 6.4 ± 4.2 0.4 ± 0.7 <0.001
Upper leg 32 10 384 120 3.3 ± 4.3 0.0 ± 0.0 0.002
Fat fraction, %
Lower extremity 26 10 515 199 15.6 ± 11.1 3.7 ± 1.5 <0.001
Lower leg 28 10 224 80 22.5 ± 18.2 2.4 ± 0.8 <0.001
Upper leg 29 10 342 119 10.3 ± 7.6 4.5 ± 2.3 0.005
Muscle volume, cm3
Lower extremity 31 10 616 200 902 ± 232 1,097 ± 251 0.028
Lower leg 32 10 256 80 276 ± 78 346 ± 81 0.024
Upper leg 32 10 377 120 619 ± 175 751 ± 175 0.056
Contractile muscle
volume, cm3
Lower extremity 26 10 515 199 779 ± 247 1,054 ± 246 0.008
Lower leg 28 10 224 80 210 ± 102 337 ± 79 0.001
Upper leg 29 10 342 119 558 ± 168 717 ± 172 0.020
T2 relaxation time, ms
Lower extremity 22 10 396 197 33.5 ± 1.0 31.9 ± 0.6 <0.001
Lower leg 23 10 147 77 34.3 ± 1.6 32.2 ± 0.7 <0.001
Upper leg 23 10 268 120 33.0 ± 1.3 31.7 ± 0.7 0.004
Abbreviation: DM1 = myotonic dystrophy type 1.
Outcome measures are presented as mean ± SD at the participant level.
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stepwise model comparison using the Akaike information
criterion confirmed this as the most informative model. The 2
participants withAciI-sensitive variant repeats and a successful
fat fraction calculation had lower mean fat fractions than the
other patients with DM1 (3.7% vs 16.0%, Welch t test, p =
0.002; figure e-5, available from Dryad, doi.org/10.5061/
dryad.4nb96c1).
Fat fraction and contractile muscle volume
correlate with disease severity and
physical performance
We investigated whether the quantitative MRI biomarkers
explored in this study correlate with clinical features of the
disease. The average lower extremity fat fraction correlated
with the MIRS disease severity score (ρ = 0.537, p = 0.005;
figure 5A). However, the MIRS score did not correlate with
contractile muscle volume (ρ = −0.197, p = 0.335; figure 5B),
muscle volume (ρ = −0.119, p = 0.525), and T2water (ρ =
0.389, p = 0.074). In the 2 patients with anMIRS score of 2, in
whom a manual muscle test did not find distal weakness, 13 of
the 16 muscles in the lower legs showed a higher fat content
than these muscles in controls. In 6 of these muscles, the fat
fraction was >10%. In the 16 patients with an MIRS score of 3
in whom no proximal weakness was found in a manual muscle
test, we detected increased fat content in 54 upper leg mus-
cles, of which 37 had a fat fraction of >10%.
Both fat fraction and contractile muscle volume correlated
with the physical capacity measure 6MWT (fat fraction:
r = −0.553, p = 0.003; contractile muscle volume: r = 0.403,
p = 0.041; figure 5, C and D), but 6MWT did not correlate
with muscle volume (r = 0.245, p = 0.184) and T2water (r =
−0.251, p = 0.261). For the individual muscle groups after
Bonferroni correction, 6MWT correlated with the fat fraction
of the ankle dorsiflexors (r = −0.498, p = 0.007) and ankle
plantarflexors (r = −0.574, p = 0.001). The 6MWT did not
correlate with any of the other MRI outcome measures of the
functional muscle groups (table e-3 available from Dryad, doi.
org/10.5061/dryad.4nb96c1).
Discussion
In this international multicenter cross-sectional quantitative
MRI study, we observed ≈3 times more fat, an ≈26% reduction
in muscle mass, and increased values for MRI markers of path-
ologic edema in 20 lower extremity muscles of patients with
DM1 compared to unaffected controls. In these genetically and
clinically well-characterized patients with DM1, quantitative
MRI measures correlated with age, CTG repeat length, and
clinical outcomes for physical capacity and disease severity.
Using quantitative MRI derived muscle fat fractions, we ob-
served more fat infiltration in muscles of patients with DM1
than in unaffected controls. This fat infiltration was more
severe in distal muscles than proximal muscles, corresponding
with DM1 being a distal myopathy.2 The gastrocnemius
medialis and soleus were most severely affected, followed by
Figure 2 Typical example of T1-weighted and TIRM images of lower extremity muscles
(A) T1-weighted image of the lower leg of an unaffected control. (B) T1-weighted image of the lower leg of a patient with myotonic dystrophy type 1 (DM1)
showing fat infiltration in the soleus (white arrow). (C) T1-weighted image of the upper leg of an unaffected control. (D) T1-weighted image of the upper leg of
a patient with DM1 showing fat infiltration in the vastimuscles and hamstringmuscles (white arrows). (E) Turbo inversion recoverymagnitude (TIRM) image of
the lower leg of an unaffected control. (F) TIRM image of the lower leg of a patient with DM1 showing hyperintense lesions reflecting edema associated with
disease activity in the soleus (white arrow). (G) TIRM image of the upper leg of an unaffected control. (H) TIRM image of the upper leg of aDM1 patient showing
hyperintense lesions in the vastus lateralis and medialis (white arrow), while fat infiltration results in a hypointense signal in the vastus intermedius and
medialis (grey arrow).
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the tibialis anterior. In contrast, clinically, ankle dorsiflexion
weakness appears to dominate plantarflexion weakness. MRI
changes may precede the soleus and gastrocnemius clinical
weakness, considering that strength measurements of this
strong muscle group are difficult to assess. In agreement with
the magnetic resonance results, force measurements using
a dynamometer showed a similar decline in ankle plantar-
flexion and ankle dorsiflexion.25 In the upper leg, the vastus
intermedius was the most severely fat-infiltrated muscle. This
corresponds with the qualitative observation of a preferential
semilunar anterolateral perifemoral area of fatty infiltration on
T1-weighted images.9 The typical fat infiltration pattern
recorded by our quantitative MRI investigation largely agrees
with the semiquantitative Lamminen score in this and other
qualitative MRI studies.9,26–29 However, in the objective as-
sessment of disease severity and progression and the evalua-
tion of clinical trials, quantitative analysis of MRIs covering
entire muscles—as presented in this study—is essential. To
date, only 1 quantitative MRI study, limited to the tibialis
anterior, has been performed in DM1.30 Although the results
of the MRI-determined changes in fat fraction identify it as
a promising biomarker to assess treatments, its real value must
be investigated in longitudinal studies.31
An interesting feature of the lower extremity muscles of
patients with DM1 is their distribution over different levels of
fat infiltration. This shows that, in patients with DM1, the
higher the fat content in muscles is, the less prevalent they are,
which is reflected in a pyramid-like shape for their distribution
over different fat fractions. This is in contrast to lower ex-
tremity muscles in patients with facioscapulohumeral dys-
trophy, in whom a quasi-binary distribution over low and high
fat infiltration was observed.32,33 This suggests that fat in-
filtration progresses more gradually in the muscles of patients
with DM1 than in the muscles of patients facioscapulo-
humeral dystrophy, in which individually affected muscles
exhibit a relatively fast transition from apparently normal to
completely fat infiltrated.
By quantitative MRI, we determined an average reduction in
muscle volume and contractile muscle volume in patients with
DM1 compared to unaffected controls, in line with an earlier
observation for the tibialis anterior.30 Reduced muscle cross-
sectional areas have also been reported for Duchenne mus-
cular dystrophy, Charcot-Marie-Tooth 1A, and inclusion
body myositis.34,35 The reduced muscle volume in patients
with DM1, containing both fat and muscle tissue, indicates
Figure 3 Quantitative MRI measures in unaffected controls vs patients with DM1
(A) Fat fraction. (B) Muscle volume. (C) Contractile muscle volume. (D) Example of a T2 water relaxation time (T2water) map of the upper leg of a patient with
myotonic dystrophy type 1 (DM1) showing increased T2water in the adductormagnus (white arrow). (E) T2water. (F) Difference in T2water compared to unaffected
controls (rT2water) in non–fat-infiltrated (non-fat) and fat-infiltrated muscles (fat) of patients with DM1. Data are presented as Tukey boxplots. *** p < 0.001.
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that contractile muscle volume is reduced by muscle atrophy
and fat infiltration. These findings support the use of muscle
volume and contractile muscle volume as MRI biomarkers to
monitor changes in muscle mass.
To analyze the presence of putative edema associated with
disease activity, we determined the Malattia score on TIRM
images and the T2water. We found an increased sum Malattia
score and increased average T2water in the muscles of patients
Figure 4 Fat infiltration pattern in the lower extremity muscles of patients with DM1
(A and B) Typical examples of fat fraction maps in the lower leg muscles of patients with myotonic dystrophy type 1 (DM1) showing fat infiltration as
hyperintense areas. (C and D) Typical examples of fat fraction maps in the upper leg muscles of patients with DM1. (E) Fat infiltration pattern of the lower leg
muscles presented as Tukey boxplots. (F) Fat infiltration pattern in the upper legmuscles presented as Tukey boxplots. (G) Prevalence of fat infiltration in the
lower legmuscles; each dot represents 1muscle in 1 patient. (H) Prevalence of fat infiltration in the upper legmuscles. AM/AL = adductormagnus/longus; BFS/
BFL = biceps femoris short/long head; EDL = extensor digitorum longus; FDL = flexor digitorum longus; G = gracilis; GL/GM= gastrocnemius lateralis/medialis;
P = peroneus; RF = rectus femoris; S = sartorius; SM = semimembranosus; SOL = soleus; ST = semitendinosus; TA/TP = tibialis anterior/posterior; VL/VI/VM =
vastus lateralis/intermedius/medialis.
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with DM1. The results indicate that edema-associated pro-
cesses occur before the presence of fat infiltration; i.e., 20% of
the muscle with a Lamminen score of 1 had aMalattia score of
1 or 2, and T2water was increased in non–fat-infiltrated mus-
cles. Increased T2water in muscles with apparently normal fat
fractions was also observed in Pompe disease, Duchenne
muscular dystrophy, inclusion body myositis, and Charcot-
Marie-Tooth 1A.35–37 This suggests that T2water is an early
marker of pathologic changes in muscles of patients with
DM1 and may be useful for evaluating early treatment effects.
Increased T2water indicates edema caused by inflammation,
necrosis, or swelling of myocytes, although, as in other mus-
cular dystrophies, it remains unknown what the precise ori-
gins are for the observed increases in all cases.6
After establishing the fat fractions for the lower extremity
muscles of patients with DM1, we compared the amount of fat
infiltration in these muscles with determinants of disease se-
verity, i.e., age and CTG repeat length. In our patients with
DM1, age explained ≈45% of the between-participant varia-
tion in fat fraction. This variation is attributed mainly to the
progressive nature of DM1 because in healthy volunteers the
effect of age is negligibly small (1%–2% higher fat fraction in
elderly compared to young persons).38 An additional amount
of this variation was explained by the estimated progenitor
allele length (≈48%) and individual-specific residual variation
in somatic instability (≈59%). This suggests that ongoing
somatic CTG expansions accrued during a patient’s lifetime
directly contribute to disease severity, as was established for
age at onset.39 Previously, a relation between the radiologic
scoring of T1-weighted images and the average CTG repeat
length at time of recruitment was observed.28 Furthermore,
the patients with DM1 who carried AciI-sensitive variant
repeats, most likely CCG or CGG variants, exhibited a slower
increase in fat fractions than patients with DM1 without de-
tectable variant repeats. This is consistent with the literature
on the effect of variant repeats and is probably mediated via
the stabilizing effect of variant repeats reducing the rate of
somatic expansion.14–16 Individual parameters or interactions
in the multivariate regression models were not significant, and
only 2 patients with AciI-sensitive variant repeats were
assessed. Nevertheless, our data highlight the value of genetic
profiling for future randomized controlled trials, because age
and CTG repeat length determine the severity of muscle in-
volvement at baseline and most likely its progression over
time.
Figure 5 Quantitative MRI measures vs disease severity and physical capacity
(A) Fat fraction vsmuscular impairment rating scale (MIRS). (B) Contractilemuscle volume vsMIRS. (C) Fat fraction vs 6-minutewalk test. (D) Contractilemuscle
volume vs 6-minute walk test.
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Finally, we investigated whether the quantitative MRI out-
comemeasures reflect disease severity and physical capacity of
the patients with DM1. We observed that the 6MWT results
correlate with fat fraction and contractile muscle volume and
that theMIRS disease score correlates with fat fraction. This is
in agreement with other DM1 studies that showed correla-
tions between semiquantitatively scored fat infiltration and
6MWT and between fat infiltration and contractile muscle
volume of the tibialis anterior and ankle dorsiflexion
torque.28,30 The fat fraction in the ankle dorsiflexors and
plantarflexors had the best correlation with the 6MWT, in-
dicating that assessment of the lower leg gives a good repre-
sentation of the patient’s physical capacity. The probable
reason is that in DM1 these muscles are affected earliest.
Furthermore, we observed in patients with an MIRS score of
2, in whom no distal weakness is expected, increased fat
fractions in lower leg muscles and in patients with an MIRS
score of 3, in whom no proximal weakness is expected, an
increased fat fraction in upper leg muscles. This demonstrates
that quantitative MRI can detect subclinical muscle in-
volvement and thus may serve in the prediction of clinical
muscle affliction. This capacity of quantitative MRI has also
been observed for other muscular dystrophies and further
emphasizes its value as a potential tool in the evaluation of
therapies.32,40–42
We observed 1 outlier, a patient with a low 6MWT (50 m)
and a relatively normal fat fraction (12.5%) and contractile
muscle volume (938 cm3). In this case, the 6MWT likely
reflected this patient’s overall condition or motivation as
opposed to muscle function alone. This further illustrates the
more objective value of quantitative MRI in assessing muscle
involvement in DM1, as has been established for other mus-
cular dystrophies.6,43
Quantitative MRI of 20 different lower extremity muscles in
33 patients with DM1 demonstrated increased fat infiltration,
reduced contractile muscle mass, and the presence of putative
edema, the last reflected by an elevated T2water. Fat infiltration
was determined primarily by age, followed by inherited CTG
repeat length, and ongoing CTG repeat expansion accrued
over time. Abnormal MRI parameter values correlated with
decreased physical capacity and disease severity but also
identified subclinical involvement and therefore can poten-
tially serve as objective, quantitative biomarkers to assess
disease state and to evaluate therapies. For the latter, larger
longitudinal natural history studies are required for validation.
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